2026年欧洲血液学会（EHA）年会暨第31届欧洲血液学协会大会（以下简称EHA 2026年会）将于当地时间2026年6月11日-14日在瑞典斯德哥尔摩隆重召开。注射用埃普奈明（aponermin商品名:沙艾特）相关的多项研究成果中选壁报展示环节，内容涵盖多发性骨髓瘤患者在接受CAR-T治疗前的桥接治疗探索，以及联合双特异性抗体、细胞毒类药物、XPO-1抑制剂、CD38单抗、免疫调节剂等多种不同作用机制的药物用于复发难治多发性骨髓瘤的治疗尝试，以及与BCL-2抑制剂协同效应的体外试验探索等。注射用埃普奈明为人肿瘤坏死因子相关凋亡诱导配体（TRAIL）的环化变构体，是全球首个上市的DR4/DR5激动剂，通过结合肿瘤细胞膜上的死亡受体4（DR4）和/或死亡受体5（DR5）激活外源性细胞凋亡通路，触发细胞内含半胱氨酸的天冬氨酸蛋白水解酶（Caspase）的级联反应，诱导不依赖P53的细胞凋亡。此外，多项研究表明，DR4／DR5激动剂还具有免疫调节作用，对肿瘤微环境中的调节性T细胞、肿瘤相关巨噬细胞、骨髓源性抑制细胞等具有抑制作用，有助于改善肿瘤免疫微环境。

本次会议由全球血液学领域最具影响力的学术组织之一——欧洲血液学协会（EHA）主办，并将采用线上线下结合的形式连接全球血液同仁。作为全球血液学领域极具权威性与影响力的顶尖学术盛会，EHA年会一直被誉为行业发展的“风向标”。本届大会将吸引来自全球100多个国家超17,000名专业人士齐聚一堂，汇聚全球血液学领域权威专家、临床医师、科研学者及患者权益倡导者等。本届大会不仅是展示前沿研究成果的宏大舞台，也是推动血液病诊疗水平提升、促进国际多中心合作的关键桥梁。

注射用埃普奈明在EHA 2026年会多篇摘要被选为壁报展示，体现了国际血液学界对死亡受体激动剂用于血液肿瘤治疗前景的进一步认可，武汉海特生物制药股份有限公司也将再接再厉，加速推进现有研究进展，早日为患者带来更多安全、有效、创新的治疗选择。

The 2026 Annual Congress of the European Hematology Association (EHA), namely the 31st EHA Congress, will be grandly held in Stockholm, Sweden, from June 11 to 14 (local time), 2026. Multiple research achievements related to Aponermin for Injection (brand name: SunHiTrail) have been selected for the poster session. The research scope includes the exploration of bridging therapy prior to CAR-T therapy in patients with multiple myeloma, the therapeutic exploration of combining with bispecific antibodies, cytotoxic drugs and other agents with distinct mechanisms of action for relapsed and refractory multiple myeloma, as well as in vitro research on the synergistic effect with BCL-2 inhibitors. As a circularly permuted endogenous human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), Aponermin for Injection is the world’s first marketed DR4/DR5 agonist. It activates the exogenous apoptosis pathway by binding to death receptor 4 (DR4) and/or death receptor 5 (DR5) on tumor cell membranes, triggering a cascade reaction of intracellular cysteine-aspartic proteases (Caspases) and inducing p53-independent apoptosis. Furthermore, numerous studies have shown that DR4/DR5 agonists exert immunomodulatory effects, which can suppress regulatory T cells, tumor-associated macrophages, myeloid-derived suppressor cells and other immunosuppressive cells in the tumor microenvironment, thereby helping remodel and optimize the tumor immune microenvironment.

Hosted by the European Hematology Association (EHA), one of the most influential academic organizations in the global hematology community, the 2026 EHA Congress will adopt a hybrid online-offline format to connect hematology professionals worldwide. As a top academic event with high authority and influence in global hematology, the EHA Annual Congress is hailed as the "vane" of industrial development. This year’s congress will gather over 17,000 professionals from more than 100 countries worldwide, including leading global hematology experts, clinicians, researchers and patient advocacy representatives. It serves not only as a prestigious platform for presenting cutting-edge research findings, but also as a critical bridge for advancing the diagnosis and treatment of hematological diseases and promoting international multicenter cooperation.

The selection of multiple Aponermin abstracts for poster presentation at the upcoming EHA Annual Congress highlights the promising clinical prospects of death receptor agonists in treating hematological malignancies, as recognized by the international hematology community. Wuhan Hiteck Biopharmaceutical Co., Ltd.will continue to accelerate the progress of ongoing clinical and preclinical research, and strive to bring more safe, effective and innovative treatment options to patients at an early date.